ALK and melanoma: The potential for ALK as a therapeutic target for advanced melanoma has been addressed by Wiesner et al. who in their characterization of the ALKATI isoform, found that its activity could be inhibited by three ALK inhibitors (crizotinib, ceritinib, and TAE-684) when incubated with ALKATI- expressing cell lines [101].